Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis

			Fair Value Measurements Using
	Balance at June 30, 2022		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Money market fund (1)	$	67,684	$	67,684	$	-	$	-
Marketable equity securities		1,173		1,173		-		-
Liabilities:
Warrants to purchase Cell Cure ordinary shares		4		-		-		4

			Fair Value Measurements Using
	Balance at December 31, 2021		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Money market fund (1)	$	52,324	$	52,324	$	-	$	-
Marketable equity securities		2,616		2,616		-		-
Liabilities:
Warrants to purchase Cell Cure ordinary shares		227		-		-		227

(1) Included in cash and cash equivalents in the accompanying condensed consolidated balance sheet.

Schedule of Changes in Fair Value

The following table sets forth the establishment of the fair value of these warrants, as well as a summary of the changes in the fair value and other adjustments (in thousands):

	Cell Cure Warrants
Balance as of December 31, 2021	$	227
Change in fair value and other adjustments		(223	)
Expiration of warrants		-
Balance as of June 30, 2022	$	4